{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:25:10Z","timestamp":1762431910048},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,12]]},"DOI":"10.7759\/cureus.10412","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T15:53:51Z","timestamp":1599926031000},"source":"Crossref","is-referenced-by-count":7,"title":["The Future of Metformin in the Prevention of Diabetes-Related Osteoporosis"],"prefix":"10.7759","author":[{"given":"Myat","family":"Aung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saba","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azouba","family":"Gulraiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenil R","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio A","family":"Pena Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilal Haider","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-199712151-00003","article-title":"Osteoporosis: definition and clinical presentation","volume":"22","author":"Glaser DL","year":"1997","unstructured":"Glaser DL, Kaplan FS. Osteoporosis: definition and clinical presentation. Spine (Phila Pa 1976). 1997, 22:12-16. 10.1097\/00007632-199712151-00003","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref2","unstructured":"International Osteoporosis Foundation. The global burden of osteoporosis. a factsheet. (2017). Accessed: May 7, 2020: https:\/\/www.iofbonehealth.org\/data-publications\/fact-sheets\/global-burden-osteoporosis."},{"key":"ref3","article-title":"Global Report on Diabetes","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global Report on Diabetes. World Health Organization, Geneva, Switzerland; 2016."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4097","article-title":"Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature","volume":"28","author":"Shah VN","year":"2017","unstructured":"Shah VN, Harrall KK, Shah CS, Gallo TL, Joshee P, Snell-Bergeon JK, Kohrt WM. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature. Osteoporos Int. 2017, 28:2601-2610. 10.1007\/s00198-017-4097","journal-title":"Osteoporos Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-006-0253-4","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis","volume":"18","author":"Vestergaard P","year":"2007","unstructured":"Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2014a meta-analysis. Osteoporos Int. 2007, 18:427-444. 10.1007\/s00198-006-0253-4","journal-title":"Osteoporos Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.7.1196","article-title":"Bone mineral density in patients with type 1 and type 2 diabetes","volume":"22","author":"Tuominen JT","year":"1999","unstructured":"Tuominen JT, Impivaara O, Puukka P, R\u00f6nnemaa T. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care. 1999, 22:1196-1200. 10.2337\/diacare.22.7.1196","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2676-7","article-title":"Biochemical markers of bone turnover in diabetes patients\u2014a meta-analysis, and a methodological study on the effects of glucose on bone markers","volume":"25","author":"Starup-Linde J","year":"2014","unstructured":"Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients\u2014a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014, 25:1697-1708. 10.1007\/s00198-014-2676-7","journal-title":"Osteoporos Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.1.7139","article-title":"Older women with diabetes have an increased risk of fracture: a prospective study","volume":"86","author":"Schwartz AV","year":"2001","unstructured":"Schwartz AV, Sellmeyer DE, Ensrud KE, et al.. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001, 86:32-38. 10.1210\/jcem.86.1.7139","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0614","article-title":"Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study","volume":"91","author":"Bonds DE","year":"2006","unstructured":"Bonds DE, Larson JC, Schwartz AV, et al.. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006, 91:3404-3410. 10.1210\/jc.2006-0614","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4269-4","article-title":"Diabetes, bone and glucose-lowering agents: basic biology","volume":"60","author":"Lecka-Czernik B","year":"2017","unstructured":"Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia. 2017, 60:1163-1169. 10.1007\/s00125-017-4269-4","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.032","article-title":"Metformin; an old antidiabetic drug with new potentials in bone disorders","volume":"109","author":"Bahrambeigi S","year":"2019","unstructured":"Bahrambeigi S, Yousefi B, Rahimi M, et al.. Metformin; an old antidiabetic drug with new potentials in bone disorders. Biomed Pharmacother. 2019, 109:1593-1601. 10.1016\/j.biopha.2018.11.032","journal-title":"Biomed Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.090732","article-title":"Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies","volume":"25","author":"Molinuevo MS","year":"2010","unstructured":"Molinuevo MS, Schurman L, McCarthy AD, et al.. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res. 2010, 25:211-221. 10.1359\/jbmr.090732","journal-title":"J Bone Miner Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-014-0258-3","article-title":"The prevention of fragility fractures in diabetic patients","volume":"27","author":"Gonnelli S","year":"2015","unstructured":"Gonnelli S, Caffarelli C, Giordano N, Nuti R. The prevention of fragility fractures in diabetic patients. Aging Clin Exp Res. 2015, 27:115-124. 10.1007\/s40520-014-0258-3","journal-title":"Aging Clin Exp Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2020.1718092","article-title":"Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study","volume":"36","author":"Bl\u00fcmel JE","year":"2020","unstructured":"Bl\u00fcmel JE, Arteaga E, Aedo S, et al.. Metformin use is associated with a lower risk of osteoporosis in adult women independent of type 2 diabetes mellitus and obesity. REDLINC IX study. Gynecol Endocrinol. 2020, 36:421-425. 10.1080\/09513590.2020.1718092","journal-title":"Gynecol Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0212-z","article-title":"Metformin prevents vascular damage in hypertension through the AMPK\/ER stress pathway","volume":"42","author":"Chen C","year":"2019","unstructured":"Chen C, Kassan A, Casta\u00f1eda D, Gabani M, Choi S-K, Kassan M. Metformin prevents vascular damage in hypertension through the AMPK\/ER stress pathway. Hypertens Res. 2019, 42:960-969. 10.1038\/s41440-019-0212-z","journal-title":"Hypertens Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00617","article-title":"The potential effect of metformin on cancer: an umbrella review","volume":"10","author":"Yu H","year":"2019","unstructured":"Yu H, Zhong X, Gao P, et al.. The potential effect of metformin on cancer: an umbrella review. Front Endocrinol (Lausanne). 2019, 10:617. 10.3389\/fendo.2019.00617","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080323","article-title":"Fracture risk in type 2 diabetes: update of a population-based study","volume":"23","author":"Melton LJ 3rd","year":"2008","unstructured":"Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res. 2008, 23:1334-1342. 10.1359\/jbmr.080323","journal-title":"J Bone Miner Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3876957","article-title":"Type 2 diabetes mellitus increases the risk to hip fracture in postmenopausal osteoporosis by deteriorating the trabecular bone microarchitecture and bone mass","volume":"2019","author":"Mohsin S","year":"2019","unstructured":"Mohsin S, Kaimala S, Sunny JJ, Adeghate E, Brown EM. Type 2 diabetes mellitus increases the risk to hip fracture in postmenopausal osteoporosis by deteriorating the trabecular bone microarchitecture and bone mass. J Diabetes Res. 2019, 2019:3876957. 10.1155\/2019\/3876957","journal-title":"J Diabetes Res"},{"key":"ref19","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe CMO","year":"2018","unstructured":"Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018, 9:119.","journal-title":"Cell Death Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9570616","article-title":"Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes","volume":"2019","author":"Yang P","year":"2019","unstructured":"Yang P, Feng J, Peng Q, Liu X, Fan Z. Advanced glycation end products: potential mechanism and therapeutic target in cardiovascular complications under diabetes. Oxid Med Cell Longev. 2019, 2019:9570616. 10.1155\/2019\/9570616","journal-title":"Oxid Med Cell Longev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12834","article-title":"Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt\/\u03b2-catenin signalling pathway via DNA methylation","volume":"53","author":"Li Y","year":"2020","unstructured":"Li Y, Wang L, Zhang M, et al.. Advanced glycation end products inhibit the osteogenic differentiation potential of adipose-derived stem cells by modulating Wnt\/\u03b2-catenin signalling pathway via DNA methylation. Cell Prolif. 2020, 53:12834. 10.1111\/cpr.12834","journal-title":"Cell Prolif"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190705211705","article-title":"An overview on stem cells in tissue regeneration","volume":"25","author":"Seetharaman R","year":"2019","unstructured":"Seetharaman R, Mahmood A, Kshatriya P, Patel D, Srivastava A. An overview on stem cells in tissue regeneration. Curr Pharm Des. 2019, 25:2086-2098. 10.2174\/1381612825666190705211705","journal-title":"Curr Pharm Des"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2014.14055","article-title":"Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis","volume":"144","author":"Ipseiz N","year":"2014","unstructured":"Ipseiz N, Scholtysek C, Culemann S, Kr\u00f6nke G. Adopted orphans as regulators of inflammation, immunity and skeletal homeostasis. Swiss Med Wkly. 2014, 144:14055. 10.4414\/smw.2014.14055","journal-title":"Swiss Med Wkly"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-010-0016-1","article-title":"PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism","volume":"8","author":"Lecka-Czernik B","year":"2010","unstructured":"Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep. 2010, 8:84-90. 10.1007\/s11914-010-0016-1","journal-title":"Curr Osteoporos Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.02.001","article-title":"Osteocalcin and its endocrine functions","volume":"132","author":"Mizokami A","year":"2017","unstructured":"Mizokami A, Kawakubo-Yasukochi T, Hirata M. Osteocalcin and its endocrine functions. Biochem Pharmacol. 2017, 132:1-8. 10.1016\/j.bcp.2017.02.001","journal-title":"Biochem Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i18.1345","article-title":"Osteocalcin as a hormone regulating glucose metabolism","volume":"6","author":"Kanazawa I","year":"2015","unstructured":"Kanazawa I. Osteocalcin as a hormone regulating glucose metabolism. World J Diabetes. 2015, 6:1345-1354. 10.4239\/wjd.v6.i18.1345","journal-title":"World J Diabetes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2019.00051","article-title":"Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations","volume":"8","author":"Kumar R","year":"2020","unstructured":"Kumar R, Priyadarshi RN, Anand U. Non-alcoholic fatty liver disease: growing burden, adverse outcomes and associations. J Clin Transl Hepatol. 2020, 8:76-86. 10.14218\/JCTH.2019.00051","journal-title":"J Clin Transl Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1589\/jpts.31.621","article-title":"Osteoporosis complication is a risk factor for frailty in females with type 2 diabetes mellitus","volume":"31","author":"Tamura H","year":"2019","unstructured":"Tamura H, Miyamoto T, Tamaki A, et al.. Osteoporosis complication is a risk factor for frailty in females with type 2 diabetes mellitus. J Phys Ther Sci. 2019, 31:621-624. 10.1589\/jpts.31.621","journal-title":"J Phys Ther Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2017.01.005","article-title":"AMPK signalling in health and disease","volume":"45","author":"Carling D","year":"2017","unstructured":"Carling D. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017, 45:31-37. 10.1016\/j.ceb.2017.01.005","journal-title":"Curr Opin Cell Biol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.05.135","article-title":"Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation","volume":"476","author":"Ming W","year":"2016","unstructured":"Ming W, Lu G, Xin S, et al.. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016, 476:412-419. 10.1016\/j.bbrc.2016.05.135","journal-title":"Biochem Biophys Res Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093240","article-title":"The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective","volume":"21","author":"Agius L","year":"2020","unstructured":"Agius L, Ford BE, Chachra SS. The metformin mechanism on gluconeogenesis and AMPK activation: the metabolite perspective. Int J Mol Sci. 2020, 21:3240. 10.3390\/ijms21093240","journal-title":"Int J Mol Sci"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.744490","article-title":"Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells","volume":"117","author":"Xie Z","year":"2008","unstructured":"Xie Z, Dong Y, Scholz R, Neumann D, Zou M-H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation. 2008, 117:952-962. 10.1161\/CIRCULATIONAHA.107.744490","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000256090.42690.05","article-title":"AMP-activated protein kinase in metabolic control and insulin signaling","volume":"100","author":"Towler MC","year":"2007","unstructured":"Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007, 100:328-341. 10.1161\/01.RES.0000256090.42690.05","journal-title":"Circ Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2007.10.004","article-title":"Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders [Article in French, English]","volume":"33","author":"Viollet B","year":"2007","unstructured":"Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders [Article in French, English]. Diabetes Metab. 2007, 33:395-402. 10.1016\/j.diabet.2007.10.004","journal-title":"Diabetes Metab"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00110.2018","article-title":"AMPK activation by A-769662 and 991 does not affect catecholamine-induced lipolysis in human adipocytes","volume":"315","author":"Kopietz F","year":"2018","unstructured":"Kopietz F, Berggreen C, Larsson S, et al.. AMPK activation by A-769662 and 991 does not affect catecholamine-induced lipolysis in human adipocytes. Am J Physiol Endocrinol Metab. 2018, 315:1075-1085. 10.1152\/ajpendo.00110.2018","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nature23275","article-title":"Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK","volume":"548","author":"Zhang CS","year":"2017","unstructured":"Zhang CS, Hawley SA, Zong Y, et al.. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature. 2017, 548:112-116. 10.1038\/nature23275","journal-title":"Nature"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9203934","article-title":"Role of metformin on osteoblast differentiation in type 2 diabetes","volume":"2019","author":"Jiating L","year":"2019","unstructured":"Jiating L, Buyun J, Yinchang Z. Role of metformin on osteoblast differentiation in type 2 diabetes. Biomed Res Int. 2019, 2019:9203934. 10.1155\/2019\/9203934","journal-title":"Biomed Res Int"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2019.1649270","article-title":"GPR39 agonist TC-G 1008 promotes osteoblast differentiation and mineralization in MC3T3-E1 cells","volume":"47","author":"Chai X","year":"2019","unstructured":"Chai X, Zhang W, Chang B, et al.. GPR39 agonist TC-G 1008 promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Artif Cells Nanomed Biotechnol. 2019, 47:3569-3576. 10.1080\/21691401.2019.1649270","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2017.0225","article-title":"Current understanding of RANK signaling in osteoclast differentiation and maturation","volume":"40","author":"Park JH","year":"2017","unstructured":"Park JH, Lee NK, Lee SY. Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells. 2017, 40:706-713. 10.14348\/molcells.2017.0225","journal-title":"Mol Cells"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12714","article-title":"Suppression of AMP-activated protein kinase reverses osteoprotegerin-induced inhibition of osteoclast differentiation by reducing autophagy","volume":"53","author":"Tong X","year":"2020","unstructured":"Tong X, Zhang C, Wang D, et al.. Suppression of AMP-activated protein kinase reverses osteoprotegerin-induced inhibition of osteoclast differentiation by reducing autophagy. Cell Prolif. 2020, 53:e12714. 10.1111\/cpr.12714","journal-title":"Cell Prolif"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/boc.202000008","article-title":"AMP-activated protein kinase (AMPK) regulates autophagy, inflammation and immunity and contributes to osteoclast differentiation and functionabs","volume":"[Epub ahead of print]","author":"Tong X","year":"2020","unstructured":"Tong X, Ganta RR, Liu Z. AMP-activated protein kinase (AMPK) regulates autophagy, inflammation and immunity and contributes to osteoclast differentiation and functionabs. Biol Cell. 2020, [Epub ahead of print]:10.1111\/boc.202000008","journal-title":"Biol Cell"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0242-2","article-title":"Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus","volume":"15","author":"Foretz M","year":"2019","unstructured":"Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019, 15:569-589. 10.1038\/s41574-019-0242-2","journal-title":"Nat Rev Endocrinol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.09.070","article-title":"Metformin improves mitochondrial respiratory activity through activation of AMPK","volume":"29","author":"Wang Y","year":"2019","unstructured":"Wang Y, An H, Liu T, et al.. Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. 2019, 29:1511-1523. 10.1016\/j.celrep.2019.09.070","journal-title":"Cell Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey CJ","year":"2017","unstructured":"Bailey CJ. Metformin: historical overview. Diabetologia. 2017, 60:1566-1576. 10.1007\/s00125-017-4318-z","journal-title":"Diabetologia"},{"key":"ref45","article-title":"World Health Organization Model List of Essential Medicines: 21st List 2019","author":"World Health Organization","unstructured":"World Health Organization. World Health Organization Model List of Essential Medicines: 21st List 2019. World Health Organization, Geneva, Switzerland; \u200e2019."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.9400","article-title":"Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis","volume":"316","author":"Palmer SC","year":"2016","unstructured":"Palmer SC, Mavridis D, Nicolucci A, et al.. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA. 2016, 316:313-324. 10.1001\/jama.2016.9400","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter RW","year":"2018","unstructured":"Hunter RW, Hughey CC, Lantier L, et al.. Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med. 2018, 24:1395-1406. 10.1038\/s41591-018-0159-7","journal-title":"Nat Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton MD","year":"2013","unstructured":"Fullerton MD, Galic S, Marcinko K, et al.. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 2013, 19:1649-1654. 10.1038\/nm.3372","journal-title":"Nat Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2018.04.004","article-title":"Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes","volume":"112","author":"Stage TB","year":"2018","unstructured":"Stage TB, Christensen MH, J\u00f8rgensen NR, Beck-Nielsen H, Br\u00f8sen K, Gram J, Frost M. Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes. Bone. 2018, 112:35-41. 10.1016\/j.bone.2018.04.004","journal-title":"Bone"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.05.016","article-title":"Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin","volume":"101","author":"Tolosa MJ","year":"2013","unstructured":"Tolosa MJ, Chuguransky SR, Sedlinsky C, Schurman L, McCarthy AD, Molinuevo MS, Cortizo AM. Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract. 2013, 101:177-186. 10.1016\/j.diabres.2013.05.016","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/39715-the-future-of-metformin-in-the-prevention-of-diabetes-related-osteoporosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:38Z","timestamp":1707506558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/39715-the-future-of-metformin-in-the-prevention-of-diabetes-related-osteoporosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.10412","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,12]]}}}